Larimar Therapeutics Inc. (NASDAQ: LRMR)
$10.06
-0.5250 ( -4.96% ) 269.4K
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Market Data
Open
$10.06
Previous close
$10.58
Volume
269.4K
Market cap
$641.21M
Day range
$9.85 - $10.57
52 week range
$2.18 - $13.68
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 57 | Jun 10, 2024 |
4 | Insider transactions | 2 | Jun 03, 2024 |
4 | Insider transactions | 1 | May 31, 2024 |
4 | Insider transactions | 1 | May 31, 2024 |
4 | Insider transactions | 1 | May 31, 2024 |
4 | Insider transactions | 1 | May 31, 2024 |
8-k | 8K-related | 11 | May 31, 2024 |
4 | Insider transactions | 1 | May 31, 2024 |
8-k | 8K-related | 13 | May 30, 2024 |
8-k | 8K-related | 58 | May 20, 2024 |